Crizotinib-induced Photoallergic Dermatitis: A Case Report of an Unconventional Adverse Effect of a Novel Molecule

ABSTRACT

Crizotinib is a novel tyrosine kinase inhibitor approved globally for the treatment of patients with locally advanced or metastatic non-small cell lung carcinoma (NSCLC) which is anaplastic lymphoma kinase (ALK) positive. It is an ATP‑competitive small‑molecule inhibitor of the receptor tyrosine kinases, namely, c‑Met, ALK, and ROS 1. Cutaneous toxicity is encountered in >50% of patients on tyrosine kinase inhibitors and they include acne‑like (acneiform) rash, discoloration, dryness, and hyperkeratosis of the skin, perifollicular inflammation, acral erythema, panniculitis, paronychia, periungual splinter hemorrhages, alopecia, facial hypertrichosis, and changes in the structure of the eyelashes, hair, and nails. Crizotinib frequently results in gastrointestinal disturbances, visual impairment, peripheral edema, QT‑prolongation, and liver enzyme elevation. Photoallergic dermatitis with crizotinib is rare. We hereby report a case of a 50‑year‑old male with ROS 1 positive metastatic adenocarcinoma of the lung on crizotinib who presented with multiple well‑ to ill‑defined erythematous plaques over both photo exposed and covered sites involving the face, neck, chest, shoulder, forearms, and dorsum of both hands. Based on the history, temporal association with the intake of the drug and histopathological evidence, a diagnosis of photo‑allergic dermatitis was made. Lesions regressed in 4 weeks with the use of oral and topical steroids, emollients, and strict photoprotection. Regular, prophylactic, photoprotective measures in patients on photosensitizing drugs like crizotinib reduces the overall morbidity and improves their quality of life.

KEYWORDS

• Crizotinib
• nonsmall cell lung cancer
• photoallergic dermatitis
• receptor tyrosine kinase inhibitor

Showing references and in-text citations exactly as published.

Cite this article

• DOI10.4103/jpp.JPP_106_18Copy

RELATED ARTICLES

Matched on section and article type within this issue of J Pharmacol. Pharmacother..

• Article · VOLUME 9, ISSUE 4Complete Response to Afatinib in Lung Adenocarcinoma of Epidermal Growth Factor Receptor Exon-19 Deletion Mutation and Disease Recurrence on Drug DiscontinuationRashmi Kumari, Emmanuel James, K. Pavithran · pp. 191–4Case ReportSame type: Article
• Article · VOLUME 9, ISSUE 4Impact of Concomitant Use of Beta blocker, Statin, Aspirin, and Metformin on Central Hemodynamics and Arterial Stiffness in HypertensionJayesh Dalpatbhai Solanki, Hemant B. Mehta, Sunil J. Panjwani, Hirava B. Munshi, Chinmay J. Shah · pp. 167–173Same type: Article
• Article · VOLUME 9, ISSUE 4A Randomized Open‑label Study to Evaluate the Effects of Escitalopram and Mirtazapine on Psychomotor Functions and Memory in Patients with DepressionAnal Modi, Mira Desai, Samidh Shah, Minaxi Parikh · pp. 174–179Same type: Article
• Article · VOLUME 9, ISSUE 4A Novel Potential Role of Vitamin K2‑7 in Relieving Peripheral NeuropathyDilip S. Mehta, Yogesh A. Dound, Shashank S. Jadhav, Abhay A. Bhave, Milind Devale, Ashok D. B. Vaidya · pp. 180–185Same type: Article